This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Zai Lab Limited Unsponsored ADR (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The Zacks Analyst Blog Highlights Zai Lab, Li Auto, Dingdong (Cayman), Autohome and JD.com
by Zacks Equity Research
Zai Lab, Li Auto, Dingdong (Cayman), Autohome and JD.com are part of the Zacks top Analyst Blog.
Why China Stocks Are Surging This Week
by Sejuti Banerjea
China has its share of problems, yet China stocks appear to be surging this week.
Seagen's (SGEN) Q3 Earnings Miss, Revenues Surpass Estimates
by Zacks Equity Research
Seagen (SGEN) reports a wider-than-expected loss in the third quarter of 2022 while its revenues beat estimates. The company raises total revenue guidance for 2022.
Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?
by Zacks Equity Research
Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to generate incremental sales and combat stiff competition.
Why Earnings Season Could Be Great for Zai Lab (ZLAB)
by Zacks Equity Research
Zai Lab (ZLAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Wall Street Analysts Think Zai Lab Limited Unsponsored ADR (ZLAB) Could Surge 145%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Zai Lab Limited Unsponsored ADR (ZLAB) points to a 144.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.
Deciphera (DCPH) Q3 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Deciphera (DCPH) reports wider-than-expected loss and revenue miss in the third quarter. It is gearing up for multiple developments and pipeline updates in the fourth quarter.
Entasis' (ETTX) Phase III Study on Infection Drug Meets Goal
by Zacks Equity Research
Entasis' (ETTX) phase III ATTACK study achieves primary endpoint. The study evaluates its investigational combo drug SUL-DUR in infections caused by Acinetobacter baumannii.
Wayfair (W) Celebrates Cinco de Mayo with Big Q1 Beat (revised)
by Mark Vickery
With reopening beginning in certain states around the country, we may see levels of commercial activity reminiscent of this past St Patrick's Day -- a long 7 weeks ago.
Wayfair (W) Celebrates Cinco de Mayo with Big Q1 Beat
by Mark Vickery
With reopening beginning in certain states around the country, we may see levels of commercial activity reminiscent of this past St Patrick's Day -- a long 7 weeks ago.
Q1 Earnings and Economic Data Deluge
by Zacks Equity Research
Q1 Earnings and Economic Data Deluge
Is Zai Lab Limited Unsponsored (ZLAB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ZLAB) Outperforming Other Medical Stocks This Year?
Will Zai Lab Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Zai Lab.
Zacks.com featured expert Kevin Matras highlights: Meet, Zai Lab, NanoString Technologies, OSI Systems and AudioEye
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Meet, Zai Lab, NanoString Technologies, OSI Systems and AudioEye
5 Stocks With Recent Price Strength to Enhance Your Return
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Moving Average Crossover Alert: Zai Lab Limited
by Zacks Equity Research
Zai Lab Limited Unsponsored ADR (ZLAB) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Will Zai Lab Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Zai Lab Limited (ZLAB).
Zai Lab (ZLAB) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Zai Lab (ZLAB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails
by Zacks Equity Research
Shares of Zai Lab (ZLAB) decline following the failure of a phase IIA study on its pipeline candidate, ZL-3101, for the treatment of atopic dermatitis.